CommercialCoverageLow impact
06.02.39d, Measurement of Serum Antibodies to and Measurement of Serum Levels of Biologics
Independence Blue Cross·Gastroenterology, Rheumatology, Dermatology +2 more·Medical Policy
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued policy 06.02.39d with no substantive changes—this is a routine annual policy review. The policy continues to classify measurement of serum antibodies to and serum levels of biologics (infliximab, adalimumab, ustekinumab, vedolizumab, and DoseASSURE™ test portfolio) as experimental/investigational and therefore NOT COVERED. Six CPT codes (80145, 80187, 80230, 80235, 80280, 80285) remain designated for these non-covered tests. Billing teams should ensure claims using these codes are denied as non-covered services rather than processed for payment.
Action Required
No immediate action required. This is a reissue with no changes to coverage status or coding. However, billing teams should verify that claims submitted with CPT codes 80145 (Adalimumab), 80230 (Infliximab), 80280 (Vedolizumab), and related codes are being consistently denied as non-covered experimental/investigational services rather than processed for reimbursement. Confirm with billing system administrators that denial rules are active for these codes under Independence Blue Cross Commercial plans. Update internal documentation if needed to reflect that these codes remain on the non-covered list as of the most recent policy reissue (09/16/2026).